scholarly journals Clinicopathological factors associated with tumour‐specific mutation detection in plasma of patients with RAS ‐ or BRAF ‐mutated metastatic colorectal cancer

2021 ◽  
Author(s):  
Julian Hamfjord ◽  
Tormod Kyrre Guren ◽  
Bengt Glimelius ◽  
Halfdan Sorbye ◽  
Per Pfeiffer ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Mutation Detection ◽  
Clinicopathological Factors ◽  
Specific Mutation ◽  
Factors Associated

scholarly journals Factors Associated With Regorafenib Adherence With Metastatic Colorectal Cancer

2019 ◽  
Vol Volume 13 ◽  
pp. 1745-1750
Author(s):  
Kazuyoshi Kawakami ◽  
Takeru Wakatsuki ◽  
Azusa Soejima ◽  
Kazuo Kobayashi ◽  
Takashi Yokokawa ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Factors Associated

Classic or simplified LV5FU2 regimen: Multivariate analysis from a phase III study in metastatic colorectal cancer in elderly patients.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 3550-3550
Author(s):  
Jean-Louis Legoux ◽  
Thomas Aparicio ◽  
Emilie Maillard ◽  
Jean Marc Phelip ◽  
Jean-Louis Jouve ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Multivariate Analysis ◽  
Prognostic Factors ◽  
Elderly Patients ◽  
Metastatic Colorectal Cancer ◽  
Folinic Acid ◽  
Phase Iii ◽  
Second Line ◽  
Factors Associated ◽  
Third Line

3550 Background: In the early 2000s, classic LV5FU2 (C) (folinic acid, 5FU bolus, then 5FU infusion on D1 and D2) was replaced with simplified LV5FU2 (S) (folinic acid and 5FU bolus on D1 only), considered as effective and less toxic. No trial proved this assertion. The LV5FU2 companion in the FOLFIRI or FOLFOX regimen was C or S. The FFCD 2001-02 study compared in a 2 x 2 factorial design, in not-pretreated elderly patients (75+) with metastatic colorectal cancer, C or S, with or without irinotecan. No significant differences in PFS and OS were observed in the comparison with or without irinotecan. The median OS was 15.2 months in C versus 11.4 months in S, HR = 0.71 (0.55–0.92) and objective response rate was 37.1% in C vs S 25.6% in S, p = 0.004. The aim of this study was to present the factors associated with these differences. Methods: Prognostic factors associated with OS were studied using a Cox model. The multivariate analysis used the significantly different items from the univariate analysis and the differences observed at the inclusion. For each of these items, a subgroup analysis was performed. The second- and third-line treatments were analysed. Results: The 282 patients from the intent-to-treat study were included in the model. In OS, the prognostic factors were C versus S, number of metastatic sites, alkaline phosphatases (AP) and CEA. The interaction test in each subgroup for OS was not significant but C was significantly better in the following subgroup: age > 80 years, male, Karnofsky 100%, 1-2 Charlson index, AP ≤ 2N, leucocyte count > 11,000, CEA > 2N, CA 19-9 ≤2N. No differences were observed in the NCI toxicities but 130 serious adverse events in S versus 102 in C. A second-line was used for 55% patients in C, 46% in S, 81% of them with oxaliplatin or irinotecan in C, 76% after S. The third-line administration (20%) and targeted therapy (15%) were similar in C and S. Conclusions: C-LV5FU2 was superior both in subgroups with better and lower prognostics and this difference cannot be explained by an imbalance between the populations. The toxicity was not higher and a second-line was more often possible after C. The switch from C to S without scientific proof was perhaps a mistake in our practices. Clinical trial information: NCT00303771.

scholarly journals KRAS and NRAS mutation detection in circulating DNA from patients with metastatic colorectal cancer using BEAMing assay: Concordance with standard biopsy and clinical evaluation

2020 ◽  
Vol 21 (1) ◽  
pp. 1-1
Author(s):  
Elena Lastraioli ◽  
Lorenzo Antonuzzo ◽  
Beatrice Fantechi ◽  
Luisa Di Cerbo ◽  
Alessandro Di Costanzo ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Clinical Evaluation ◽  
Mutation Detection ◽  
Circulating Dna

scholarly journals Circulating Free DNA as Biomarker and Source for Mutation Detection in Metastatic Colorectal Cancer

PLoS ONE ◽  
2015 ◽  
Vol 10 (4) ◽  
pp. e0108247 ◽  
Author(s):  
Karen Lise Garm Spindler ◽  
Niels Pallisgaard ◽  
Rikke Fredslund Andersen ◽  
Ivan Brandslund ◽  
Anders Jakobsen
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Mutation Detection ◽  
Circulating Free Dna ◽  
Free Dna

scholarly journals Factors associated with Trifluridine/Tipiracil (TAS-102) effectiveness in patients with refractory metastatic colorectal cancer: real-life data from the Czech Republic.

2019 ◽  
Author(s):  
Peter Grell ◽  
Josef Dvorak ◽  
Michal Vocka ◽  
Stanislav John ◽  
Helena Pitauerova ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Czech Republic ◽  
Clinical Practice ◽  
High Risk ◽  
Metastatic Colorectal Cancer ◽  
Scoring System ◽  
Risk Group ◽  
Real Life ◽  
The Czech Republic ◽  
Factors Associated

Abstract Background: Trifluridine/tipiracil (TAS-102) is effective in refractory metastatic colorectal cancer (mCRC). Currently, no predictive biomarkers are established and used in clinical practice. Methods: We analyzed data of 160 patients treated with TAS-102 in real clinical practice in the Czech Republic. Different factors associated with progression-free survival (PFS) and overall survival (OS) were evaluated. Results: Median PFS was 3.3 months, and median OS 10.2 months. Factors significantly associated with PFS and/or OS were: ECOG performance status (PS), time from diagnosis of mCRC > 24 months, initiation of treatment > 3 months from last fluoropyrimidine, number of metastatic sites, baseline CRP level, WBC count, neutrophils count, monocytes count, neutrophil to lymphocyte ratio, development of neutropenia, thrombocytopenia, diarrhea, required dose reduction and cycle delay. We developed a scoring system TAScore from factors available at the beginning of treatment. One point each was assigned to the following factors (PS, diagnosis of mCRC > 24 months, initiation of TAS-102 > 3 months from fluoropyrimidine, baseline CRP, WBC, monocytes count < 0.5 × 10 9 /L) and patients were divided into 3 groups: high risk group (0 to 1 point), intermediate (2 to 3), favorable with 4 or more points. OS according to risk group was: 5.7 months for high risk, 8.7 for intermediate, 12.8 for favorable (P < 0.001). TAScore was also associated with PFS (P < 0.001). Conclusions : TAS-102 is effective in patients with refractory mCRC. We propose simple scoring system TAScore to help with precise patient selection at the beginning of TAS-102 treatment.

scholarly journals Mutation Detection in Tumor-Derived Cell Free DNA Anticipates Progression in a Patient With Metastatic Colorectal Cancer

2018 ◽  
Vol 8 ◽  
Author(s):  
Bruna D. de Figueiredo Barros ◽  
Bruna E. C. Kupper ◽  
Samuel Aguiar Junior ◽  
Celso A. L. de Mello ◽  
Maria D. Begnami ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Mutation Detection ◽  
Cell Free Dna ◽  
Free Dna

scholarly journals Factors associated with the efficiency of maintenance therapy in patients with metastatic colorectal cancer

2016 ◽  
Vol 6 (2) ◽  
pp. 8-17
Author(s):  
M. Yu. Fedyanin ◽  
A. A. Tryakin ◽  
E. M. Polyanskaya ◽  
I. A. Pokataev ◽  
O. V. Sheina ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Maintenance Therapy ◽  
Metastatic Colorectal Cancer ◽  
Factors Associated
Sign in / Sign up

Export Citation Format

Share Document